Yimamuyushan A, Li Y, Jiao W, Yu J, Li J, Shi Y
Ren Fail. 2024; 46(2):2428330.
PMID: 39544106
PMC: 11571727.
DOI: 10.1080/0886022X.2024.2428330.
Wong Z, Teo C, Fiona Wong Y, Ng K, Lim S
PLoS One. 2024; 19(7):e0307981.
PMID: 39083488
PMC: 11290670.
DOI: 10.1371/journal.pone.0307981.
Nozu K, Sako M, Tanaka S, Kano Y, Ohwada Y, Morohashi T
Clin Exp Nephrol. 2023; 28(4):337-348.
PMID: 38010466
PMC: 10955017.
DOI: 10.1007/s10157-023-02431-0.
Angeletti A, Bruschi M, Kajana X, La Porta E, Spinelli S, Caridi G
Front Immunol. 2023; 14:1213203.
PMID: 37705972
PMC: 10497215.
DOI: 10.3389/fimmu.2023.1213203.
Zhong H, Li H, Zhou T, Weng W
Arch Med Sci. 2023; 19(3):577-585.
PMID: 37313189
PMC: 10259397.
DOI: 10.5114/aoms.2019.88404.
First clinical application of cord blood mesenchymal stromal cells in children with multi-drug resistant nephrotic syndrome.
Morello W, Budelli S, Bernstein D, Montemurro T, Montelatici E, Lavazza C
Stem Cell Res Ther. 2022; 13(1):420.
PMID: 35986374
PMC: 9389735.
DOI: 10.1186/s13287-022-03112-7.
Clinicopathological spectrum and treatment outcome of idiopathic steroid-resistant nephrotic syndrome in children at a tertiary care center.
Kashif A, Ranjan A, Kalra S, Shravani Uttpal D, Malik A
Med J Armed Forces India. 2022; 78(3):291-295.
PMID: 35855707
PMC: 9287659.
DOI: 10.1016/j.mjafi.2020.11.004.
Vagus Nerve Stimulation: A Potential Therapeutic Role in Childhood Nephrotic Syndrome?.
Sethna C, Merchant K, Zanos S, Deutschman C, Datta-Chaudhuri T, Chavan S
Am J Nephrol. 2022; 53(4):290-296.
PMID: 35340000
PMC: 9090973.
DOI: 10.1159/000523837.
Transcutaneous auricular vagus nerve stimulation (taVNS) for the treatment of pediatric nephrotic syndrome: a pilot study.
Merchant K, Zanos S, Datta-Chaudhuri T, Deutschman C, Sethna C
Bioelectron Med. 2022; 8(1):1.
PMID: 35078538
PMC: 8790887.
DOI: 10.1186/s42234-021-00084-6.
Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective study.
Tasdemir M, Canpolat N, Yildiz N, Ozcelik G, Benzer M, Saygili S
Turk J Med Sci. 2021; 51(4):1781-1790.
PMID: 33581711
PMC: 8569731.
DOI: 10.3906/sag-2012-297.
Early Use of Rituximab in Calcineurin Inhibitor-Refractory and Steroid-Resistant Nephrotic Syndrome.
Sinha R, Banerjee S, Mukherjee A, Pradhan S, Akhtar S
Kidney Int Rep. 2020; 5(12):2354-2357.
PMID: 33305130
PMC: 7710833.
DOI: 10.1016/j.ekir.2020.09.021.
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome.
Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F
Pediatr Nephrol. 2020; 35(8):1529-1561.
PMID: 32382828
PMC: 7316686.
DOI: 10.1007/s00467-020-04519-1.
Current understandings in treating children with steroid-resistant nephrotic syndrome.
Lee J, Kronbichler A, Shin J, Oh J
Pediatr Nephrol. 2020; 36(4):747-761.
PMID: 32086590
PMC: 7910243.
DOI: 10.1007/s00467-020-04476-9.
Molecular stratification of idiopathic nephrotic syndrome.
Saleem M
Nat Rev Nephrol. 2019; 15(12):750-765.
PMID: 31654044
DOI: 10.1038/s41581-019-0217-5.
Rituximab for Children With Difficult-to-Treat Nephrotic Syndrome: Its Effects on Disease Progression and Growth.
Topaloglu R, Gulhan B, Celegen K, Inozu M, Hayran M, Duzova A
Front Pediatr. 2019; 7:313.
PMID: 31417883
PMC: 6682627.
DOI: 10.3389/fped.2019.00313.
Rituximab Use in the Management of Childhood Nephrotic Syndrome.
Kallash M, Smoyer W, Mahan J
Front Pediatr. 2019; 7:178.
PMID: 31134169
PMC: 6524616.
DOI: 10.3389/fped.2019.00178.
Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children.
Kamei K, Ishikura K, Sako M, Ito S, Nozu K, Iijima K
Pediatr Nephrol. 2018; 35(1):17-24.
PMID: 30564879
DOI: 10.1007/s00467-018-4166-1.
Efficacy of Semiannual Single Fixed Low-Dose Rituximab Therapy in Steroid-Dependent Minimal Change Nephrotic Syndrome: A Case Series.
Usui R, Tsuchiya Y, Nitta K, Koike M
Case Rep Nephrol Dial. 2018; 8(3):230-237.
PMID: 30479998
PMC: 6244099.
DOI: 10.1159/000493189.
Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.
Ahn Y, Kim S, Han K, Choi H, Cho H, Lee J
Medicine (Baltimore). 2018; 97(46):e13157.
PMID: 30431588
PMC: 6257685.
DOI: 10.1097/MD.0000000000013157.
Treatment of steroid-resistant nephrotic syndrome in the genomic era.
Bensimhon A, Williams A, Gbadegesin R
Pediatr Nephrol. 2018; 34(11):2279-2293.
PMID: 30280213
PMC: 6445770.
DOI: 10.1007/s00467-018-4093-1.
